A complete solution for rapid molecular diagnostics of coronavirus infection
With its two complementary platform technologies Amplidiag® and Novodiag®, Mobidiag has the capacity to meet the needs of clinical laboratories and multiple healthcare settings. Currently on the market, these platforms combine high quality and affordable costs, allowing widespread use both in mass screening and on-demand highly targeted or syndromic tests for various infectious diseases. The extremely versatile product offer, the flexibility of the technologies used, and the expertise of the Mobidiag team allow great responsiveness in the development of new products in emergency situations. Rapid molecular diagnostics of coronavirus infection currently offered by Mobidiag in the case of the COVID-19 pandemic are a perfect example.
Since December 2019, COVID-19 has been spreading rapidly throughout the World. You can follow live evolution of the infection on the WHO Coronavirus Disease (COVID-19) Dashboard.
Choose the right coronavirus test based on your needs
|
|
Amplidiag® RESP-4 | Amplidiag® COVID-19 | Novodiag® COVID-19 |
| Product no. | AD-RP4-864 | AD-CV-864 | NVD-CV-012 |
| Package size | 864 tests | 864 tests | 12 cartridges |
| Sample type | Nasopharyngeal swab | Nasopharyngeal swab | Nasopharyngeal swab |
| Technology | RT-PCR | RT-PCR | RT-PCR |
| Targets | SARS-CoV-2 (N gene) SARS-CoV-2 (E gene) Influenza A (M gene) Influenza B (NS gene) RSV A/B (M gene) |
SARS-CoV-2 (orf1ab) SARS-CoV-2 (N) |
SARS-CoV-2 (orf1ab) SARS-CoV-2 (N) |
| Time to results | 46 samples in ~3h turnaround time with Amplidiag® Easy platform | 55min for amplification <3h with Amplidiag® Easy platform |
1h20 |
| Availability | CE-IVD | CE-IVD | CE-IVD |
Mobidiag offers complementary molecular tests for coronavirus infection diagnostics: targeted panels with Novodiag® COVID-19 and Amplidiag® COVID-19, and a wider, syndromic, panel allowing simultaneous detection of COVID-19, Flu A, Flu B and RSV with Amplidiag® RESP-4 and upcoming Novodiag® RESP-4.
In the Winter season, COVID-19, Flu A, Flu B and RSV infections are highly prevalent. Symptoms following these respiratory infections are overlapping, it is then quite difficult to determine which virus is responsible for a specific symptom to guide diagnostics, and in fine to the relevant treatment. As a result, Mobidiag is now offering Amplidiag® RESP-4 allowing distinction between these 4 key targets: SARS-CoV-2, Influenza A, Influenza B and RSV.
Amplidiag® COVID-19, Novodiag® COVID-19 and Amplidiag® RESP-4 are now CE-IVD. For on-demand testing, we are currently developing Novodiag® RESP-4. Please contact us for more information.
⊗ Please note that Mobidiag tests are not home testing kits. As a result, they are only available for healthcare professionals, and not for patients directly. Based on your location, follow the recommended process if you believe you could be infected by SARS-CoV-2.
Key Advantages
- A complete solution for rapid and reliable molecular diagnostics of targeted coronavirus infection (COVID-19) and syndromic for most common respiratory infections (COVID-19, Flu A, Flu B, RSV)
- Sample quality control to prevent false negative results
- A test for all sample volumes (by batch or on-demand testing)
- Self-sufficient in production and securing of raw materials to ensure continuity of testing throughout the complete workflow, from sample collection to results
Dedicated tests
Amplidiag® RESP-4
CE-IVD. For in vitro diagnostic use.
Amplidiag® RESP-4 test allows the rapid detection of novel coronavirus, Flu A, Flu B and RSV infections. By allowing rapid and reliable detection of the viruses responsible for these infections simultaneously, this qualitative real-time RT-PCR test supports decisions to manage efficiently epidemiological and infection control measures, isolate patients in a timely manner and improve patient care globally.
- SARS-CoV-2 (N gene)
- SARS-CoV-2 (E-gene)
- Influenza A (M gene)
- Influenza B (NS gene)
- RSV A/B (M gene)
CE-IVD. For in vitro diagnostic use.
- Product no: AD-RP4-864
- Package size: 864 tests
- Product format: Amplification kit for multiplex RT-PCR
- Sample material: RNA extracted from nasopharyngeal sample
- Time to results: ~3h for 46 samples
Compatibility
- Compatible with the Amplidiag® Easy instrument
- Differentiate COVID-19 from other common Winter respiratory infections
- Suited for high-throughput molecular diagnostics
- Runs on multiplex RT-PCR technology for optimal performance
- Automated and easy result analysis with Amplidiag® Analyzer software
- Workflow automation possible with Amplidiag® Easy:
- Automated process for RNA extraction and PCR set up
- Streamline your laboratory process and sample flow
- Optimize your sample screening process
- Report same-day results (46 samples in ~3h turnaround time)
- Coming soon
Novodiag® COVID-19
CE-IVD
Novodiag® COVID-19 test operates using the on demand rapid ‘sample-in, result-out’ Novodiag® system, allowing the rapid detection of novel coronavirus in 1h20.
This fully automated solution protects laboratory staff from potential contamination. With its user-friendly nature, the Novodiag® COVID-19 solution can be delivered to high risk and hard to reach areas, as well as decentralized laboratories, without the need for highly trained personnel.
This qualitative real-time RT-PCR test supports decisions to manage efficiently epidemiological and infection control measures, isolate patients in a timely manner and improve patient care globally.
Please note that Mobidiag tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Based on your location, follow the recommended process if you believe you could be infected by SARS-CoV-2.
- SARS-CoV-2 (orf1ab)
- SARS-CoV-2 (N)
Novodiag® COVID-19 detects 2 molecular targets including at least one conserved region and one specific region to mitigate against the effects of genetic drift and avoid cross-reaction with other endemic coronaviruses.
CE-IVD
- Product no: NVD-CV-012
- Package size: 12 Test Cartridges
- Sample type: Nasopharyngeal sample
- Time to result: 1h20
Compatibility
- Cartridge compatible with the Novodiag® instrument
- Two molecular targets to mitigate against the effects of genetic drift and avoid cross-reaction with other endemic coronaviruses
- Single and ready to use test cartridge containing everything necessary to perform the assay
- On demand testing
- Real-time RT-PCR technology
- Internal cellularity control
- Easy to use and interpret
- Results in 1h20
- Easily disposable
- Shipping and storage at room temperature
- Coming soon
Amplidiag® COVID-19
CE-IVD
Amplidiag® COVID-19 test allows the rapid detection of novel coronavirus for large volumes (by batch). By allowing rapid and reliable detection of this novel coronavirus, this qualitative real-time RT-PCR test supports decisions to manage efficiently epidemiological and infection control measures, isolate patients in a timely manner and improve patient care globally.
Please note that Mobidiag tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Based on your location, follow the recommended process if you believe you could be infected by SARS-CoV-2.
- SARS-CoV-2 (orf1ab)
- SARS-CoV-2 (N)
Amplidiag® COVID-19 detects 2 molecular targets including at least one conserved region and one specific region to mitigate against the effects of genetic drift and avoid cross-reaction with other endemic coronaviruses.
CE-IVD
- Product no: AD-CV-864
- Package size: 864 tests
- Product format: Amplification kit for multiplex RT-PCR
- Sample material: RNA extracted from nasopharyngeal sample
- Two molecular targets to mitigate against the effects of genetic drift and avoid cross-reaction with other endemic coronaviruses
- Large volumes on batches
- Runs on multiplex RT-PCR technology for optimal performance
- Automated and easy result analysis with Amplidiag® Analyzer software
- Workflow automation possible with Amplidiag® Easy:
- Automated process for DNA extraction and PCR set up
- Streamline your laboratory process and sample flow
- Optimize your sample screening process
- Report same-day results (48 samples in <3h turnaround time)
- Coming soon